BLISSGVS — Bliss GVS Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapHigh Flyer

Annual income statement for Bliss GVS Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	5,772	7,475	7,516	7,702	8,097
Cost of Revenue
Gross Profit	2,402	3,482	3,431	3,777	3,960
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	4,878	7,200	6,529	6,752	7,125
Operating Profit	894	274	986	950	973
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,041	542	1,061	1,169	1,256
Provision for Income Taxes
Net Income After Taxes	740	231	767	816	903
Minority Interest
Net Income Before Extraordinary Items
Net Income	685	150	709	755	843
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	685	150	709	755	843
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	6.5	4.42	6.69	9.02	7.95
Dividends per Share